Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study

  • Authors:
    • Zhi‑Liang Huang
    • Xun Cao
    • Ruo‑Zhen Luo
    • You‑Fang Chen
    • Lin‑Chun Zhu
    • Zhesheng Wen
  • View Affiliations

  • Published online on: November 9, 2015     https://doi.org/10.3892/ol.2015.3894
  • Pages: 299-305
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although adjuvant platinum-based chemotherapy has been demonstrated to improve survival in patients with completely resected non‑small cell lung cancer (NSCLC), individualized approaches to therapy are urgently required to improve the treatment efficacy and reduce unnecessary toxicity. It was hypothesized in the present study that the protein levels of excision repair cross‑complementation group 1 (ERCC1), breast cancer 1 (BRCA1), ribonucleotide reductase M1 (RRM1) and class III β‑tubulin (TUBB3) may influence the therapeutic effect of adjuvant cisplatin‑based chemotherapy. The expression of ERCC1, BRCA1, RRM1 and TUBB3 in tissues obtained from 84 patients with NSCLC was analyzed in the present non‑interventional study by immunohistochemistry prior to adjuvant chemotherapy. All patients received adjuvant cisplatin‑based chemotherapy. The primary endpoint in the present study was disease free survival (DFS). Out of the 84 tumors, the expression of ERCC1, BRCA1, RRM1 and TUBB3 was identified in 46 (55%), 11 (13%), 73 (87%) and 76 (90%) tissues, respectively. A beneficial response to adjuvant cisplatin‑based chemotherapy in DFS was associated with the absence of the expression of ERCC1 [hazard ratio (HR), 2.166; 95% confidence interval (CI), 1.049‑4.474; P=0.037] and BRCA1 (HR, 2.419; 95% CI, 1.127‑5.193; P=0.023), but not with the expression status of RRM1 (HR, 0.568; 95% CI, 0.234‑1.379; P=0.212) or TUBB3 (HR, 1.874; 95% CI, 0.448‑7.842; P=0.39). In addition, patients lacking the expression of ERCC1 and BRCA1 benefited more from adjuvant cisplatin‑based chemotherapy compared with patients that expressed either ERCC1 or BRCA1 (HR, 3.102; 95% CI, 1.343‑7.163; P=0.008). The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin‑based chemotherapy, respectively. The combination of the ERCC1 and BRCA1 expression levels may be a promising prognostic prediction for adjuvant cisplatin-based chemotherapy.
View Figures
View References

Related Articles

Journal Cover

January-2016
Volume 11 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang ZL, Cao X, Luo RZ, Chen YF, Zhu LC and Wen Z: Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study. Oncol Lett 11: 299-305, 2016
APA
Huang, Z., Cao, X., Luo, R., Chen, Y., Zhu, L., & Wen, Z. (2016). Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study. Oncology Letters, 11, 299-305. https://doi.org/10.3892/ol.2015.3894
MLA
Huang, Z., Cao, X., Luo, R., Chen, Y., Zhu, L., Wen, Z."Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study". Oncology Letters 11.1 (2016): 299-305.
Chicago
Huang, Z., Cao, X., Luo, R., Chen, Y., Zhu, L., Wen, Z."Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study". Oncology Letters 11, no. 1 (2016): 299-305. https://doi.org/10.3892/ol.2015.3894